Last reviewed · How we verify

Atezolizumab & Bevacizumab — Competitive Intelligence Brief

Atezolizumab & Bevacizumab (Atezolizumab & Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor + VEGF inhibitor combination. Area: Oncology.

phase 3 PD-L1 inhibitor + VEGF inhibitor combination PD-L1 and VEGF Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Atezolizumab & Bevacizumab (Atezolizumab & Bevacizumab) — IRCCS Azienda Ospedaliero-Universitaria di Bologna. Atezolizumab blocks PD-L1 to restore anti-tumor immunity, while bevacizumab inhibits VEGF to reduce tumor angiogenesis, together enhancing immune-mediated tumor control.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Atezolizumab & Bevacizumab TARGET Atezolizumab & Bevacizumab IRCCS Azienda Ospedaliero-Universitaria di Bologna phase 3 PD-L1 inhibitor + VEGF inhibitor combination PD-L1 and VEGF

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor + VEGF inhibitor combination class)

  1. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  2. Tae Won Kim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atezolizumab & Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/atezolizumab-bevacizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: